Related Experiment Video
Updated: Feb 25, 2026
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
Therapeutic Role and Immunogenic Characteristics of Cancer Testis Antigens in Breast Cancer: A Review
Motahareh Sheikh-Hosseini1,2, Mostafa Neissi3,4,5, Mohammad Moarefzadeh6
1Department of Medical Genetics, Institute of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran.
Abstract:
Breast cancer remains a leading cause of cancer-related deaths among women globally, presenting significant challenges due to its heterogeneity and complex biology. While traditional treatments such as surgery, chemotherapy, and targeted therapies offer some benefit, the lack of universal treatment strategies underscores the need for innovative approaches. A total of 255 articles were identified through PubMed, Scopus, Web of Science, and Google Scholar up to 1 December 2025, and 30 articles were selected for inclusion in this narrative review. This narrative review focuses on cancer-testis antigens (CTAs) as potential therapeutic targets in breast cancer. The objective of this narrative review is to evaluate the therapeutic role and immunogenic characteristics of CTAs in breast cancer, with emphasis on their potential in diagnosis, prognosis, and immunotherapy. CTAs are tumor-associated antigens that are aberrantly expressed in various cancers, including breast cancer, while their expression in normal tissues is restricted to the testis. Their unique immunogenic properties make them ideal candidates for both early diagnostic tools and targeted immunotherapy. This article discusses the potential of CTAs in improving breast cancer screening, prognosis, and treatment strategies, with particular emphasis on their roles in immunotherapy and vaccine development. Furthermore, the challenges of CTA-based treatments, including antigen heterogeneity and immune evasion, are outlined, along with insights into future research directions aimed at overcoming these obstacles and improving clinical outcomes.
Insights
Cancer-testis antigens (CTAs) show promise as novel targets for breast cancer immunotherapy and diagnostics. Research highlights their potential to improve screening, prognosis, and treatment strategies, despite challenges like antigen heterogeneity.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Breast cancer is a leading cause of death in women, characterized by heterogeneity and complex biology.
- Current treatments like chemotherapy and targeted therapies have limitations, necessitating innovative therapeutic strategies.
- Cancer-testis antigens (CTAs) are aberrantly expressed in tumors, including breast cancer, but restricted to normal testicular tissue.
Purpose of the Study:
- To evaluate the therapeutic potential and immunogenic characteristics of CTAs in breast cancer.
- To explore the role of CTAs in breast cancer diagnosis, prognosis, and immunotherapy.
- To review current literature on CTA-based breast cancer treatment strategies and future research directions.
Main Methods:
- A narrative review of 255 articles identified from major scientific databases (PubMed, Scopus, Web of Science, Google Scholar) up to December 2025.
- Selection of 30 relevant articles for in-depth analysis and synthesis of findings.
- Focus on CTA expression, immunogenicity, and therapeutic applications in breast cancer.
Main Results:
- CTAs possess unique immunogenic properties, making them suitable for early diagnostic tools and targeted immunotherapy in breast cancer.
- CTAs demonstrate potential for improving breast cancer screening, prognosis assessment, and treatment efficacy.
- The review identifies challenges in CTA-based treatments, including antigen heterogeneity and immune evasion mechanisms.
Conclusions:
- CTAs represent a promising avenue for developing novel immunotherapies and diagnostic/prognostic tools for breast cancer.
- Overcoming challenges such as antigen heterogeneity and immune evasion is crucial for advancing CTA-based breast cancer treatments.
- Further research into CTA-based strategies, including vaccine development, is warranted to improve clinical outcomes for breast cancer patients.
More Related Videos
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
09:53Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
Published on: February 6, 2017
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:38Mitogens and the Cell Cycle
02:17The Tumor Microenvironment
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...